Catalyst

Slingshot members are tracking this event:

European Commission Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Secondary Hyperparathyroidism, Hemodialysis, Parsabiv, Etelcalcetide, Chronic Kidney Disease